文献速递冠心病心力衰竭与心肌病心律失常

左心室附壁血栓患者的抗血栓治疗:预后与管理

Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该研究基于90,065份超声心动图报告筛选出159例确诊左心室附壁血栓(LVT)患者,评估抗凝治疗对血栓演变的影响及血栓消退与血栓栓塞、出血和死亡的关系。中位随访632天,MACE发生率为37.1%,死亡18.9%;完全血栓消退与死亡率降低独立相关(HR 0.48)。

要点

  • LVT患者MACE和死亡风险很高,中位随访632天MACE达37.1%、死亡18.9%。
  • 完全LVT消退(62.3%)与死亡率降低独立相关(HR 0.48,95%CI 0.23-0.98)。
  • 抗凝>3个月和LVEF≥35%与较少MACE独立相关。

核心结论

  • LVT的存在与极高的MACE和死亡风险相关。
  • 不同抗凝方案获得的完全LVT消退与死亡率降低相关。

研究设计与样本

  • 回顾性研究,2011年1月至2018年1月,通过90,065份连续超声心动图报告计算机化搜索LVT。
  • 经2名独立专家影像复核,仅纳入确诊LVT患者159例。

主要发现

  • 121例(76.1%)LVT面积较基线减小,99例(62.3%)完全消退,中位时间103天(IQR 32-392天)。
  • 中位随访632天(IQR 187-1126天),MACE 37.1%,死亡18.9%,卒中13.3%,大出血13.2%。
  • 完全LVT消退者与持续LVT者MACE发生率分别为35.4%和40.0%(p=0.203)。
  • 完全LVT消退与死亡率降低独立相关(HR 0.48;95%CI 0.23-0.98;p=0.039)。
  • LVEF≥35%(HR 0.46;95%CI 0.23-0.93;p=0.029)和抗凝治疗>3个月(HR 0.42;95%CI 0.20-0.88;p=0.021)与较少MACE独立相关。

关键数值与推荐

  • LVT消退的独立相关因素:非缺血性心肌病(HR 2.74;95%CI 1.43-5.26;p=0.002)和较小基线血栓面积(HR 0.66;95%CI 0.45-0.96;p=0.031)。
  • 持续LVT者大出血风险增加(9.1% vs 12%;HR 0.34;95%CI 0.14-0.82;p=0.011)。
  • 抗凝方案:维生素K拮抗剂48.4%,肠外肝素27.7%,直接口服抗凝药22.6%;抗血小板治疗67.9%。

临床怎么用

  • 对LVT患者应充分抗凝并监测血栓演变,抗凝>3个月与较少MACE相关。
  • 完全血栓消退与死亡率降低相关,支持序贯影像评估血栓消退。
  • 持续LVT者需警惕大出血风险,权衡抗凝强度与出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary data are lacking regarding the prognosis and management of left ventricular thrombus (LVT). OBJECTIVES: The purpose of this study was to quantify the effect of anticoagulation therapy on LVT evolution using sequential imaging and to determine the impact of LVT regression on the incidence of thromboembolism, bleeding, and mortality. METHODS: From January 2011 to January 2018, a comprehensive computerized search of LVT was conducted using 90,065 consecutive echocardiogram reports. Only patients with a confirmed LVT were included after imaging review by 2 independent experts. Major adverse cardiovascular events (MACE), which included death, stroke, myocardial infarction, or acute peripheral artery emboli, were determined as well as major bleeding events (BARC ≥3) and all-cause mortality rates. RESULTS: There were 159 patients with a confirmed LVT. Patients were treated with vitamin K antagonists (48.4%), parenteral heparins (27.7%), and direct oral anticoagulants (22.6%). Antiplatelet therapy was used in 67.9% of the population. A reduction of the LVT area from baseline was observed in 121 patients (76.1%), and total LVT regression occurred in 99 patients (62.3%) within a median time of 103 days (interquartile range: 32 to 392 days). The independent correlates of LVT regression were a nonischemic cardiomyopathy (hazard ratio [HR]: 2.74; 95% confidence interval [CI]: 1.43 to 5.26; p = 0.002) and a smaller baseline thrombus area (HR: 0.66; 95% CI: 0.45 to 0.96; p = 0.031). The frequency of MACE was 37.1%; mortality 18.9%; stroke 13.3%; and major bleeding 13.2% during a median follow-up of 632 days (interquartile range: 187 to 1,126 days). MACE occurred in 35.4% and 40.0% of patients with total LVT regression and those with persistent LVT (p = 0.203). A reduced risk of mortality was observed among patients with total LVT regression (HR: 0.48; 95% CI: 0.23 to 0.98; p = 0.039), whereas an increased major bleeding risk was observed among patients with persistent LVT (9.1% vs. 12%; HR 0.34; 95% CI: 0.14 to 0.82; p = 0.011). A left ventricular ejection fraction ≥35% (HR: 0.46; 95% CI: 0.23 to 0.93; p = 0.029) and anticoagulation therapy >3 months (HR: 0.42; 95% CI: 0.20 to 0.88; p = 0.021) were independently associated with less MACE. CONCLUSIONS: The presence of LVT was associated with a very high risk of MACE and mortality. Total LVT regression, obtained with different anticoagulant regimens, was associated with reduced mortality.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lattuca B, Bouziri N, Kerneis M, et al. Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. J Am Coll Cardiol. 2020. PMID: 32273033. doi:10.1016/j.jacc.2020.01.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。